340 related articles for article (PubMed ID: 27141355)
21. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in
Pyo KH; Lim SM; Park CW; Jo HN; Kim JH; Yun MR; Kim D; Xin CF; Lee W; Gheorghiu B; Hong MH; Kim HR; Shim HS; Jang M; Lee SS; Cho BC
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727812
[TBL] [Abstract][Full Text] [Related]
23. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
26. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
27. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
28. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
Guo Y; Ma J; Lyu X; Liu H; Wei B; Zhao J; Fu S; Ding L; Zhang J
BMC Cancer; 2014 Nov; 14():834. PubMed ID: 25407901
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
30. Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Roussel H; De Guillebon E; Biard L; Mandavit M; Gibault L; Fabre E; Antoine M; Hofman P; Beau-Faller M; Blons H; Danel C; Barthes FLP; Gey A; Granier C; Wislez M; Laurent-Puig P; Oudard S; Bruneval P; Badoual C; Cadranel J; Tartour E
Oncoimmunology; 2017; 6(4):e1286437. PubMed ID: 28507793
[TBL] [Abstract][Full Text] [Related]
31. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
32. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
[TBL] [Abstract][Full Text] [Related]
35. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
36. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
38. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
39. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
Park HR; Ahn YO; Kim TM; Kim S; Kim S; Lee YS; Kim M; Keam B; Kim DW; Heo DS
Cytotherapy; 2019 Jun; 21(6):603-611. PubMed ID: 31010733
[TBL] [Abstract][Full Text] [Related]
40. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
